Axiom Securities restated their sell rating on shares of NeoGenomics Inc. (NASDAQ:NEO) in a research note published on Wednesday.

Several other research analysts also recently weighed in on NEO. BTIG Research raised shares of NeoGenomics from a neutral rating to a buy rating and set a $10.00 target price for the company in a research note on Thursday, October 27th. Raymond James Financial Inc. initiated coverage on shares of NeoGenomics in a research note on Thursday, September 8th. They set an outperform rating and a $10.00 price objective for the company. Zacks Investment Research raised shares of NeoGenomics from a hold rating to a buy rating and set a $9.25 price objective for the company in a research note on Friday, August 5th. First Analysis initiated coverage on shares of NeoGenomics in a research note on Monday, October 3rd. They set an overweight rating and a $11.00 price objective for the company. Finally, Benchmark Co. upped their price objective on shares of NeoGenomics from $10.00 to $12.00 and gave the company a buy rating in a research note on Wednesday, July 27th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $10.43.

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

NeoGenomics (NASDAQ:NEO) traded up 0.56% during trading on Wednesday, reaching $9.01. 86,679 shares of the company’s stock were exchanged. The firm’s market capitalization is $707.40 billion. The stock has a 50-day moving average price of $8.02 and a 200 day moving average price of $8.31. NeoGenomics has a 52 week low of $5.49 and a 52 week high of $9.54.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Wednesday, October 26th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.03 by $0.01. NeoGenomics had a negative net margin of 3.10% and a positive return on equity of 3.56%. The business had revenue of $60.76 million for the quarter, compared to analyst estimates of $61 million. During the same period in the previous year, the firm earned $0.01 EPS. The business’s revenue for the quarter was up 141.8% compared to the same quarter last year. Equities research analysts forecast that NeoGenomics will post $0.14 earnings per share for the current fiscal year.

In other news, insider Maher Albitar sold 370,000 shares of the firm’s stock in a transaction on Friday, August 19th. The stock was sold at an average price of $8.23, for a total transaction of $3,045,100.00. Following the transaction, the insider now directly owns 263,492 shares of the company’s stock, valued at $2,168,539.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 12.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in NEO. Vanguard Group Inc. raised its position in NeoGenomics by 26.1% in the second quarter. Vanguard Group Inc. now owns 2,130,513 shares of the company’s stock worth $17,130,000 after buying an additional 441,119 shares during the period. Emerald Acquisition Ltd. raised its position in NeoGenomics by 16.8% in the third quarter. Emerald Acquisition Ltd. now owns 1,904,580 shares of the company’s stock worth $15,655,000 after buying an additional 273,278 shares during the period. Kopp Investment Advisors LLC raised its position in NeoGenomics by 3.4% in the second quarter. Kopp Investment Advisors LLC now owns 1,476,902 shares of the company’s stock worth $11,875,000 after buying an additional 48,354 shares during the period. BlackRock Fund Advisors raised its position in NeoGenomics by 6.3% in the third quarter. BlackRock Fund Advisors now owns 1,471,971 shares of the company’s stock worth $12,100,000 after buying an additional 87,117 shares during the period. Finally, BlackRock Institutional Trust Company N.A. raised its position in NeoGenomics by 1.1% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,366,920 shares of the company’s stock worth $11,236,000 after buying an additional 14,899 shares during the period. 78.38% of the stock is owned by institutional investors and hedge funds.

NeoGenomics Company Profile

5 Day Chart for NASDAQ:NEO

Receive News & Stock Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related stocks with our FREE daily email newsletter.